The Hang Seng Index plummeted by more than 2% in the intraday period, and Ping An Good Doctor (01833) rebounded and increased by more than 8% after the results. As of press release, it rose 1.22% to HK$13.3, with a turnover of HK$34.831 million.
The Zhitong Finance App learned that the Hang Seng Index plummeted by more than 2% in the intraday period, and Dr. Ping An (01833) reversed the market rally and turned up, rising more than 8% after the results. As of press release, it rose 1.22% to HK$13.3, with a turnover of HK$34.831 million.
After his performance, Dr. Ping An was praised by many major international companies. UBS released a research report with a target price of HK$20 for Ping An Good Doctor, stressing that the company's 2023 performance was in line with expectations, that the steady progress of Strategy 2.0 reduced losses rapidly, and that the steady growth of the F-side business combined with the rapid growth of the B-side business. Damo said that considering the further reduction in the company's adjusted net loss, and the “front-end+back-end” expansion is progressing smoothly, the target price for Ping An Good Doctor is HK$21.
Dahua Jixian said that Ping An Good Doctor completed the restructuring of the low-synergy business in 2023, and it is expected that revenue from the F-side and B-side strategic business will achieve double-digit growth in 2024. Home care services will also create a new driving force for growth. Dahua Jixian expects revenue to grow at a CAGR of 18% in 2023-25 thanks to continuous strategic upgrading efforts.